SARMs & 'Research Chemical' Mislabeling
Selective androgen receptor modulators and the Van Wagoner JAMA mislabeling analysis
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No SARM is FDA-approved; illegally sold as 'research chemicals' or supplements
Reference only. Not medical advice.
What can go wrong
Documented risks include drug-induced liver injury (some severe), suppression of natural testosterone, adverse lipid changes, and - because products are frequently mislabeled or spiked with unapproved drugs per these analyses - exposure to entirely different or undisclosed compounds. The 'not for human consumption' labeling is a legal fig leaf, not a safety statement.
This is something to take to a clinician. The Atlas can tell you what is known about sarms & 'research chemical' mislabeling in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Selective androgen receptor modulators (SARMs) such as ostarine (enobosarm), ligandrol (LGD-4033), and RAD-140 are investigational compounds, none FDA-approved, sold illegally online as 'research chemicals' or disguised as supplements. Van Wagoner and colleagues' JAMA analysis of products sold as SARMs found that only a minority actually contained the labeled SARM at the labeled amount; many contained a different drug, an unapproved drug, or no active ingredient at all. SARMs themselves carry documented risks including drug-induced liver injury, testosterone suppression, and lipid changes; the mislabeling adds an unknown-exposure problem on top. The FDA has warned that SARMs are linked to serious harms and are not dietary supplements.
Sold as 'not for human consumption' - and frequently not even the drug on the label.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
SARMs are designed to activate the androgen receptor with tissue selectivity (more muscle/bone, less prostate/skin effect than testosterone), but this selectivity is incomplete and the human safety profile is unestablished. The gray-market harm is twofold: the intrinsic, under-studied drug effects (liver injury, HPG-axis suppression, lowered HDL), and the mislabeling - this testing shows the bottle frequently does not contain what the label claims, so users cannot know their actual exposure.
Safety in detail
No selective androgen receptor modulator (SARM) is FDA-approved for any use. Products sold as SARMs are frequently mislabeled, may contain unapproved drugs or no active ingredient, and carry documented risks including liver injury. They are not dietary supplements.
- Drug-induced liver injury, including severe cases
- Testosterone suppression and lipid changes
- Frequent mislabeling per JAMA testing
- Spiking with undisclosed unapproved drugs
What people get wrong
Often said'SARMs are a safe alternative to steroids'
ActuallyThey are unapproved drugs with documented liver and endocrine harms and incomplete tissue selectivity; these analyses also show you often aren't getting the SARM you paid for.
Often said'It's a supplement, so it's regulated for content'
ActuallyThe FDA has explicitly stated SARMs are not dietary supplements; products are illegally marketed and JAMA testing found frequent mislabeling.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Long-term safety of SARMs in humans remains largely unstudied outside limited trials such as those for enobosarm
At a glance
- Key analysis
- Van Wagoner et al., JAMA (2017)
- Finding
- Many 'SARM' products mislabeled or containing unapproved drugs
- FDA status
- None approved; warned as not dietary supplements
- Documented harm
- Drug-induced liver injury, axis suppression
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about SARMs & 'Research Chemical' Mislabeling. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Van Wagoner, Eichner, Bhasin, Deuster, Eichner2017
JAMA analysis of products sold as SARMs found frequent mislabeling: many contained unapproved drugs, different drugs, or no active compound
FDA warning on SARMs / 'Tianeptine and SARMs' communications2017-2022
FDA warned SARMs are associated with serious health risks and are not legal dietary supplements